Ascendis Pharma (ASND) Stock Forecast, Price Target & Predictions
ASND Stock Forecast
Ascendis Pharma stock forecast is as follows: an average price target of $211.14 (represents a 54.82% upside from ASND’s last price of $136.38) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
ASND Price Target
The average price target for Ascendis Pharma (ASND) is $211.14 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $289.00 to $190.00. This represents a potential 54.82% upside from ASND's last price of $136.38.
ASND Analyst Ratings
According to 11 Wall Street analysts, Ascendis Pharma's rating consensus is 'Buy'. The analyst rating breakdown for ASND stock is 0 'Strong Buy' (0.00%), 10 'Buy' (90.91%), 1 'Hold' (9.09%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Ascendis Pharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 23, 2024 | Tazeen Ahmad | Bank of America Securities | $191.00 | $151.26 | 26.27% | 40.05% |
| Sep 17, 2024 | Gavin Clark-Gartner | Evercore ISI | $205.00 | $144.97 | 41.41% | 50.32% |
| Sep 17, 2024 | Leland Gershell | Oppenheimer | $190.00 | $143.90 | 32.04% | 39.32% |
| Sep 17, 2024 | David Lebowitz | Citigroup | $207.00 | $139.57 | 48.31% | 51.78% |
| Sep 17, 2024 | Derek Archila | Wells Fargo | $289.00 | $139.57 | 107.06% | 111.91% |
| Sep 16, 2024 | Tazeen Ahmad | Bank of America Securities | $175.00 | $142.26 | 23.01% | 28.32% |
| Sep 16, 2024 | Paul Choi | Goldman Sachs | $200.00 | $142.26 | 40.59% | 46.65% |
| Sep 13, 2024 | David Lebowitz | Citigroup | $178.00 | $118.00 | 50.85% | 30.52% |
| Sep 05, 2024 | Leland Gershell | Oppenheimer | $180.00 | $122.40 | 47.06% | 31.98% |
| Aug 13, 2024 | Kelly Shi | Jefferies | $196.00 | $128.48 | 52.55% | 43.72% |
| May 30, 2024 | Alex Thompson | Stifel Nicolaus | $200.00 | $137.45 | 45.51% | 46.65% |
| May 15, 2024 | Vikram Purohit | Morgan Stanley | $140.00 | $124.04 | 12.87% | 2.65% |
| Mar 14, 2024 | Josh Schimmer | Evercore ISI | $191.00 | $149.89 | 27.43% | 40.05% |
| Jan 03, 2023 | Wells Fargo | $177.00 | $118.87 | 48.90% | 29.78% | |
| Nov 15, 2022 | Morgan Stanley | $148.00 | $111.47 | 32.77% | 8.52% | |
| Nov 14, 2022 | Leerink Partners | $148.00 | $110.26 | 34.23% | 8.52% | |
| Nov 14, 2022 | Wedbush | $164.00 | $110.26 | 48.74% | 20.25% | |
| Mar 20, 2022 | Tazeen Ahmad | Bank of America Securities | $161.00 | $117.44 | 37.09% | 18.05% |
| Feb 28, 2022 | David Lebovitz | Citigroup | $187.00 | $112.39 | 66.38% | 37.12% |
| Jan 06, 2022 | Yaron Werber | Cowen & Co. | $136.00 | $121.70 | 11.75% | -0.28% |
| Jul 07, 2021 | Michelle Gilson | Canaccord Genuity | $196.00 | $126.68 | 54.72% | 43.72% |
| Jun 14, 2021 | Alethia Young | Cantor Fitzgerald | $201.00 | $134.40 | 49.55% | 47.38% |
The latest Ascendis Pharma stock forecast, released on Sep 23, 2024 by Tazeen Ahmad from Bank of America Securities, set a price target of $191.00, which represents a 26.27% increase from the stock price at the time of the forecast ($151.26), and a 40.05% increase from ASND last price ($136.38).
Ascendis Pharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 13 |
| Avg Price Target | - | $191.00 | $195.54 |
| Last Closing Price | $136.38 | $136.38 | $136.38 |
| Upside/Downside | -100.00% | 40.05% | 43.38% |
In the current month, the average price target of Ascendis Pharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Ascendis Pharma's last price of $136.38. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 15, 2024 | Citigroup | Buy | Buy | Hold |
| Oct 21, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 17, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Sep 17, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Sep 17, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Sep 16, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Sep 16, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Sep 10, 2024 | Citigroup | Buy | Buy | Hold |
| Sep 04, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 13, 2024 | Jefferies | Buy | Buy | Hold |
| Aug 12, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Jun 25, 2024 | Cowen & Co. | Buy | Positive | Upgrade |
| Jun 25, 2024 | Cowen & Co. | Buy | Upgrade | |
| Jun 12, 2024 | Bank of America Securities | Buy | Buy | Hold |
| May 16, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Jan 03, 2023 | Wells Fargo | Overweight | Overweight | Hold |
| Nov 15, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
| Nov 14, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Nov 14, 2022 | Wedbush | Outperform | Outperform | Hold |
| Aug 11, 2022 | Oppenheimer | Outperform | Outperform | Hold |
Ascendis Pharma's last stock rating was published by Citigroup on Nov 15, 2024. The company gave ASND a "Buy" rating, the same as its previous rate.
Ascendis Pharma Financial Forecast
Ascendis Pharma Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $33.59M | $22.90M | $15.29M | $6.16M | $6.83M | $4.90M | $1.11M | $1.02M | $746.00K | $535.00K | $2.76M | $1.44M | $2.23M | $2.51M | $2.24M |
| Avg Forecast | $293.11M | $291.66M | $289.74M | $288.33M | $145.46M | $118.51M | $102.39M | $85.75M | $94.45M | $70.09M | $82.80M | $79.81M | $93.73M | $49.05M | $37.24M | $21.50M | $19.15M | $8.81M | $5.60M | $4.55M | $2.71M | $1.14M | $746.43K | $1.64M | $1.69M | $1.39M | $2.18M | $2.12M | $1.90M | $1.40M |
| High Forecast | $399.85M | $397.88M | $395.25M | $393.33M | $198.44M | $161.66M | $139.68M | $90.04M | $127.25M | $95.61M | $85.38M | $82.73M | $160.04M | $50.38M | $50.80M | $29.34M | $26.13M | $8.81M | $5.60M | $4.55M | $2.71M | $1.14M | $746.43K | $1.64M | $1.69M | $1.39M | $2.18M | $2.12M | $1.90M | $1.40M |
| Low Forecast | $243.30M | $242.10M | $240.50M | $239.33M | $120.74M | $98.37M | $84.99M | $81.45M | $70.73M | $58.18M | $80.23M | $76.89M | $61.23M | $47.72M | $30.91M | $17.85M | $15.90M | $8.81M | $5.60M | $4.55M | $2.71M | $1.14M | $746.43K | $1.64M | $1.69M | $1.39M | $2.18M | $2.12M | $1.90M | $1.40M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 9 | 4 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 13 | 7 | 7 | 9 | 8 | 6 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.56% | 1.20% | 1.73% | 1.10% | 1.50% | 1.81% | 0.98% | 1.37% | 0.45% | 0.32% | 1.98% | 0.66% | 1.05% | 1.32% | 1.60% |
Ascendis Pharma's average Quarter revenue forecast for Jun 23 based on 3 analysts is $37.24M, with a low forecast of $30.91M, and a high forecast of $50.80M. ASND's average Quarter revenue forecast represents a 10.86% increase compared to the company's last Quarter revenue of $33.59M (Mar 23).
Ascendis Pharma EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 9 | 4 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 13 | 7 | 7 | 9 | 8 | 6 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-95.23M | $-176.65M | $-123.36M | $-67.54M | $-115.44M | $-100.57M | $-75.68M | $-118.68M | $-58.40M | $-174.47M | $-79.52M | $-82.55M | $-60.95M | $-78.02M | $-22.89M |
| Avg Forecast | $-293.11M | $-291.66M | $-289.74M | $-288.33M | $-145.46M | $-118.51M | $-102.39M | $-85.75M | $-94.45M | $-70.09M | $-82.80M | $-79.81M | $-93.73M | $-49.05M | $-37.24M | $-21.50M | $-19.15M | $-8.81M | $-5.60M | $-93.33M | $-2.71M | $-1.14M | $-746.43K | $-65.11M | $-1.69M | $-1.39M | $-2.18M | $-57.26M | $-1.90M | $-1.40M |
| High Forecast | $-243.30M | $-242.10M | $-240.50M | $-239.33M | $-120.74M | $-98.37M | $-84.99M | $-81.45M | $-70.73M | $-58.18M | $-80.23M | $-76.89M | $-61.23M | $-47.72M | $-30.91M | $-17.85M | $-15.90M | $-8.81M | $-5.60M | $-74.66M | $-2.71M | $-1.14M | $-746.43K | $-52.09M | $-1.69M | $-1.39M | $-2.18M | $-45.81M | $-1.90M | $-1.40M |
| Low Forecast | $-399.85M | $-397.88M | $-395.25M | $-393.33M | $-198.44M | $-161.66M | $-139.68M | $-90.04M | $-127.25M | $-95.61M | $-85.38M | $-82.73M | $-160.04M | $-50.38M | $-50.80M | $-29.34M | $-26.13M | $-8.81M | $-5.60M | $-111.99M | $-2.71M | $-1.14M | $-746.43K | $-78.13M | $-1.69M | $-1.39M | $-2.18M | $-68.72M | $-1.90M | $-1.40M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.43% | 9.22% | 14.00% | 12.07% | 1.24% | 37.10% | 66.57% | 159.00% | 0.90% | 103.20% | 57.15% | 37.87% | 1.06% | 41.09% | 16.37% |
undefined analysts predict ASND's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Ascendis Pharma's previous annual EBITDA (undefined) of $NaN.
Ascendis Pharma Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 9 | 4 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 13 | 7 | 7 | 9 | 8 | 6 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-110.91M | $-207.42M | $-168.96M | $-81.32M | $-125.50M | $-106.06M | $-80.35M | $-134.37M | $-62.79M | $-138.97M | $-121.74M | $-94.93M | $-63.32M | $-80.36M | $-25.11M |
| Avg Forecast | - | - | - | - | $-32.95M | $-51.09M | $-64.26M | $-77.19M | $-69.59M | $-89.44M | $-83.47M | $-85.03M | $-104.37M | $-136.40M | $-144.68M | $-151.90M | $-151.12M | $-146.33M | $-124.28M | $-101.46M | $-132.40M | $-131.89M | $-127.81M | $-70.00M | $-90.00M | $-90.16M | $-83.77M | $-59.48M | $-68.87M | $-68.44M |
| High Forecast | - | - | - | - | $-25.67M | $-39.80M | $-50.06M | $-67.12M | $-38.41M | $-69.68M | $-65.03M | $-66.25M | $-28.16M | $-106.26M | $-112.72M | $-118.34M | $-117.74M | $-146.33M | $-124.28M | $-81.17M | $-132.40M | $-131.89M | $-127.81M | $-56.00M | $-90.00M | $-90.16M | $-83.77M | $-47.59M | $-68.87M | $-68.44M |
| Low Forecast | - | - | - | - | $-48.55M | $-75.28M | $-94.68M | $-89.18M | $-84.96M | $-131.79M | $-122.99M | $-125.29M | $-212.63M | $-200.97M | $-213.17M | $-223.81M | $-222.67M | $-146.33M | $-124.28M | $-121.75M | $-132.40M | $-131.89M | $-127.81M | $-84.00M | $-90.00M | $-90.16M | $-83.77M | $-71.38M | $-68.87M | $-68.44M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.73% | 1.37% | 1.15% | 0.65% | 1.24% | 0.80% | 0.61% | 1.05% | 0.90% | 1.54% | 1.35% | 1.13% | 1.06% | 1.17% | 0.37% |
Ascendis Pharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ASND's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Ascendis Pharma SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 9 | 4 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 13 | 7 | 7 | 9 | 8 | 6 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $66.54M | $56.55M | $60.67M | $56.58M | $47.42M | $48.30M | $39.28M | $35.34M | $37.25M | $20.43M | $17.52M | $20.80M | $17.91M | $17.08M | $10.00M |
| Avg Forecast | $2.38B | $2.37B | $2.35B | $2.34B | $1.18B | $961.30M | $830.61M | $695.56M | $766.16M | $568.54M | $671.70M | $647.41M | $760.29M | $397.90M | $302.05M | $174.44M | $155.35M | $71.49M | $45.39M | $36.88M | $21.99M | $9.22M | $6.05M | $13.32M | $13.71M | $11.29M | $17.68M | $17.20M | $15.40M | $11.34M |
| High Forecast | $3.24B | $3.23B | $3.21B | $3.19B | $1.61B | $1.31B | $1.13B | $730.39M | $1.03B | $775.59M | $692.60M | $671.11M | $1.30B | $408.71M | $412.06M | $237.97M | $211.93M | $71.49M | $45.39M | $36.88M | $21.99M | $9.22M | $6.05M | $13.32M | $13.71M | $11.29M | $17.68M | $17.20M | $15.40M | $11.34M |
| Low Forecast | $1.97B | $1.96B | $1.95B | $1.94B | $979.46M | $797.94M | $689.46M | $660.72M | $573.76M | $471.92M | $650.80M | $623.71M | $496.67M | $387.09M | $250.73M | $144.80M | $128.95M | $71.49M | $45.39M | $36.88M | $21.99M | $9.22M | $6.05M | $13.32M | $13.71M | $11.29M | $17.68M | $17.20M | $15.40M | $11.34M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.38% | 0.36% | 0.85% | 1.25% | 1.29% | 2.20% | 4.26% | 5.84% | 2.80% | 1.49% | 1.55% | 1.18% | 1.04% | 1.11% | 0.88% |
Ascendis Pharma's average Quarter SG&A projection for Jun 23 is $302.05M, based on 3 Wall Street analysts, with a range of $250.73M to $412.06M. The forecast indicates a 353.95% rise compared to ASND last annual SG&A of $66.54M (Mar 23).
Ascendis Pharma EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 9 | 4 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 13 | 7 | 7 | 9 | 8 | 6 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-1.98 | $-3.72 | $-3.03 | $-1.46 | $-2.21 | $-1.97 | $-1.47 | $-2.50 | $-1.17 | $-2.58 | $-2.31 | $-1.97 | $-1.32 | $-1.67 | $-0.53 |
| Avg Forecast | - | - | - | - | $-0.57 | $-0.89 | $-1.12 | $-1.35 | $-1.21 | $-1.56 | $-1.46 | $-1.48 | $-1.82 | $-2.38 | $-2.52 | $-2.65 | $-2.64 | $-2.55 | $-2.17 | $-2.06 | $-2.31 | $-2.30 | $-2.23 | $-1.81 | $-1.57 | $-1.57 | $-1.46 | $-1.33 | $-1.20 | $-1.19 |
| High Forecast | - | - | - | - | $-0.45 | $-0.69 | $-0.87 | $-1.17 | $-0.67 | $-1.22 | $-1.13 | $-1.16 | $-0.49 | $-1.85 | $-1.97 | $-2.06 | $-2.05 | $-2.55 | $-2.17 | $-2.06 | $-2.31 | $-2.30 | $-2.23 | $-1.81 | $-1.57 | $-1.57 | $-1.46 | $-1.33 | $-1.20 | $-1.19 |
| Low Forecast | - | - | - | - | $-0.85 | $-1.31 | $-1.65 | $-1.56 | $-1.48 | $-2.30 | $-2.14 | $-2.18 | $-3.71 | $-3.50 | $-3.72 | $-3.90 | $-3.88 | $-2.55 | $-2.17 | $-2.06 | $-2.31 | $-2.30 | $-2.23 | $-1.81 | $-1.57 | $-1.57 | $-1.46 | $-1.33 | $-1.20 | $-1.19 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.75% | 1.41% | 1.19% | 0.67% | 1.07% | 0.85% | 0.64% | 1.12% | 0.65% | 1.64% | 1.47% | 1.35% | 0.99% | 1.39% | 0.44% |
According to undefined Wall Street analysts, Ascendis Pharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ASND previous annual EPS of $NaN (undefined).
Ascendis Pharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.37 | $33.86 | 1328.69% | Buy |
| PLRX | Pliant Therapeutics | $14.37 | $35.50 | 147.04% | Buy |
| STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
| APLS | Apellis Pharmaceuticals | $34.53 | $70.80 | 105.04% | Buy |
| AMLX | Amylyx Pharmaceuticals | $4.28 | $8.25 | 92.76% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| AKRO | Akero Therapeutics | $30.61 | $50.00 | 63.35% | Buy |
| REPL | Replimune Group | $11.72 | $19.00 | 62.12% | Buy |
| ASND | Ascendis Pharma | $140.30 | $211.14 | 50.49% | Buy |
| ETNB | 89bio | $7.98 | $12.00 | 50.38% | Buy |
| BGNE | BeiGene | $179.06 | $267.33 | 49.30% | Buy |
| ACLX | Arcellx | $82.03 | $111.60 | 36.05% | Buy |
| NUVL | Nuvalent | $88.10 | $114.80 | 30.31% | Buy |
| BPMC | Blueprint Medicines | $96.48 | $122.60 | 27.07% | Buy |
| CRNX | Crinetics Pharmaceuticals | $55.37 | $69.00 | 24.62% | Buy |
| UTHR | United Therapeutics | $379.69 | $440.40 | 15.99% | Buy |
| MDGL | Madrigal Pharmaceuticals | $306.08 | $315.75 | 3.16% | Buy |